

Girijesh Kumar Patel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9412519/publications.pdf>

Version: 2024-02-01

10
papers

493
citations

1040018

9
h-index

1372553

10
g-index

10
all docs

10
docs citations

10
times ranked

880
citing authors

#	ARTICLE	IF	CITATIONS
1	Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. <i>British Journal of Cancer</i> , 2017, 116, 609-619.	6.4	205
2	Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play. <i>Cancers</i> , 2019, 11, 1405.	3.7	70
3	Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. <i>International Journal of Molecular Sciences</i> , 2017, 18, 779.	4.1	63
4	Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer. <i>Journal of Biological Chemistry</i> , 2020, 295, 8413-8424.	3.4	35
5	Glucose Metabolism Reprogrammed by Overexpression of IKK μ Promotes Pancreatic Tumor Growth. <i>Cancer Research</i> , 2016, 76, 7254-7264.	0.9	33
6	Helicobacter pylori-Induced Inflammation: Possible Factors Modulating the Risk of Gastric Cancer. <i>Pathogens</i> , 2021, 10, 1099.	2.8	33
7	Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 416-424.	1.4	23
8	The Prevalence of DPYD*9A (c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis. <i>Clinical Colorectal Cancer</i> , 2019, 18, e280-e286.	2.3	14
9	MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer. <i>British Journal of Cancer</i> , 2022, 126, 1205-1214.	6.4	13
10	The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens. <i>Pharmacogenomics Journal</i> , 2021, 21, 308-317.	2.0	4